{
  "docId": "019de070-c58c-706c-98f1-9eec26811648",
  "docSlug": "2a1e5b2d3a1cb25fe50abb3e75ae9bdf",
  "documentTitle": "Alkermes | Investor Day Presentation Deck | 144 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 132,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 8,
  "notes": "The slide uses a combination of a summary table and a grouped bar chart to demonstrate competitive outperformance.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-c58c-706c-98f1-9eec26811648/19",
  "deckHref": "/decks/019de070-c58c-706c-98f1-9eec26811648",
  "deckJsonHref": "/decks/019de070-c58c-706c-98f1-9eec26811648.json",
  "deckAnchorHref": "/decks/019de070-c58c-706c-98f1-9eec26811648#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.45,
        "x": 0.52,
        "y": 0.25
      },
      "kind": "chart",
      "text": "ARISTADA TRx MOT Growth Rate: 2020 YoY (16% vs 5%), Q4'20 QoQ (4% vs 2%)",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4345c376-ac48-4318-a2ec-b3301e1b4149",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.5,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "*Includes ARISTADA®, Abilify Maintena® (estimated sales), Invega Sustenna/Trinza®, Risperdal Consta® and Perseris®. ** IQVIA NPA Audit. MOT: Months of therapy",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "078f7341-c60b-4999-8c67-a14b5ce3e916",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.45,
        "x": 0.05,
        "y": 0.42
      },
      "kind": "table",
      "text": "Branded Market Size: ~$3.5B; Annual TRx: ~2M; Market Share: 9% ARISTADA MOT Share",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4312b2e1-4ced-4270-b53f-e599243b4b2a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "ARISTADA®: Growth Outpaced Atypical Long-Acting Injectable (aLAI) Antipsychotic Market",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f7b2574d-6b06-4c69-bb0d-fb6bc7d5074c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Waterfall chart",
      "slug": "waterfall-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "82c78dcd-b169-44e0-9419-de4535734524",
      "evidence": "chart/bar-grouped: ARISTADA TRx MOT Growth Rate: 2020 YoY (16% vs 5%), Q4'20 QoQ (4% vs 2%)",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 10,
      "beatId": "e69bd338-b010-4d79-bb12-76f71bdac0a3",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "Slides 10-20 outline the company's value enhancement plan and strategic approach.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 23,
      "from": 15,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "016a3177-fde8-4bf5-87dc-d18694e9ff64",
      "evidence": "Slides 15-23 discuss revenue growth drivers and the importance of cost management.",
      "position": 0,
      "objective": "To highlight the cost of inaction and the benefits of Alkermes' growth strategy",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}